Agonists of peroxisome proliferators-activated receptors (PPAR) α, β/δ or γ reduce transforming growth factor (TGF)-β-induced proteoglycans' production in chondrocytes  by Poleni, P.E. et al.
Agonists of peroxisome proliferators-activated receptors (PPAR) a, b/d
or g reduce transforming growth factor (TGF)-b-induced proteoglycans’
production in chondrocytes
P. E. Poleni M.Sc., A. Bianchi Ph.D., S. Etienne M.Sc., M. Koufany B.Sc., S. Sebillaud B.Sc.,
P. Netter M.D., Ph.D., B. Terlain Pharm.D. and J. Y. Jouzeau Pharm.D., Ph.D.*
Laboratoire de Physiopathologie et Pharmacologie Articulaires (LPPA), UMR 7561 CNRS-UHP Nancy 1,
Avenue de la Foreˆt de Haye, BP 184, 54505 Vandœuvre-le`s-Nancy Cedex, France
Summary
Objective: To investigate the potency of selective agonists of peroxisome proliferators-activated receptors’ (PPAR) isotypes (a, b/d or g) to
modulate the stimulating effect of transforming growth factor-b1 (TGF-b1) on proteoglycans’ (PGs) synthesis in chondrocytes.
Method: Rat chondrocytes embedded in alginate beads and cultured under low serum conditions were exposed to TGF-b1 (10 ng/ml), alone or
in combination with the following agonists: Wy14643 for PPARa, GW501516 for PPARb/d, rosiglitazone (ROSI) for PPARg, in the presence or
absence of PPAR antagonists (GW6471 for PPARa, GW9662 for PPARg). PGs’ synthesis was evaluated by radiolabelled sulphate incorpora-
tion and glycosaminoglycans’ (GAGs) content by Alcian blue staining of beads and colorimetric 1.9 dimethyl-methylene blue assay after beads’
solubilization. Phosphorylation of Extracellular Signal-related Kinase1/2 (ERK1/2), Smad2/3 and p38-MAPKwas assessed byWestern Blot and
production of prostaglandin E2 (PGE2) by Enzyme immuno-assay (EIA). Levels of mRNA for PPAR target genes [acyl-CoA oxidase (ACO) for
PPARa; mitochondrial carnitin palmitoyl transferase-1 (CPT-1) for PPARb/d and adiponectin for PPARg], aggrecan, TGF-b1 and genes control-
ling GAGs’ side chains’ synthesis were quantiﬁed by real time polymerase chain reaction and normalized over RP29 housekeeping gene.
Results: ACO was selectively up-regulated by 100 mM of Wy14643, CPT-1 by 100 nM of GW501516 and adiponectin by 10 mM of ROSI with-
out cell toxicity. TGF-b1 increased PGs’ synthesis by four-fold, GAGs’ content and deposition by 3.5-fold and six-fold, respectively, while in-
ducing aggrecan expression around 10-fold without modifying mRNA levels of GAGs’ controlling enzymes. PPAR agonists inhibited the
stimulating effect of TGF-b1 by 24e44% on PGs’ synthesis and over 75% on aggrecan, GAGs’ content and deposition with the following
rank order of potency: ROSI>GW501516Wy14643. TGF-b1-induced phosphorylation of Smad2/3 and ERK1/2 was reduced by ROSI
over GW501516 but not by Wy14643 whereas stimulated PGE2 production was inhibited by Wy14643 over GW501516 but not by ROSI.
The effect of PPAR agonists on PPAR target genes and TGF-b1-induced aggrecan expression was reversed selectively by PPAR
antagonists.
Conclusion: In chondrocytes’ beads, PPAR agonists reduced the stimulating effect of TGF-b1 on PGs by inhibiting TGF-b1-induced aggrecan
expression in an isotype-selective manner. Thus, PPAR agonists could be deleterious in situation of cartilage repair although being protective
in situation of cartilage degradation.
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SocietyIntroduction
Transforming growth factor-b (TGF-b) is a multifunctional
cytokine that plays an important role in immunomodulation,
inﬂammation and tissue repair1. In articular cartilage, TGF-
b is a potent stimulator of chondrocytes’ proliferation and
differentiation2, stimulates synthesis of cartilage-speciﬁc
collagen type II or aggrecan3 and modulates matrix metallo-
proteases’ (MMPs) activities by increasing synthesis of their
natural tissue inhibitors4. Therefore, TGF-b is thought to
play a crucial role in the maintenance and repair of articular
cartilage, all the more that it counteracts the suppressive
effect of inﬂammatory cytokines on proteoglycans’ (PGs)
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conditions6 and stimulates PG synthesis more actively in
OA than in healthy cartilage7. Despite its beneﬁcial effects
on the turnover of matrix components, TGF-b may have
a pathological role in OA. Indeed, intra-articular administra-
tion8 or joint overexpression9 of TGF-b is inﬂammatory and
ﬁbrotic with appearance of chondrogenesis in the synovial
lining. As a common ﬁnding, repeated injection10 or sus-
tained expression9 leads to the synovial-layer-dependent
formation of osteophytes. Finally, TGF-b can induce the ex-
pression of aggrecanase-1 in human synovial ﬁbroblasts11
and chondrocytes12 with the subsequent release of ma-
trix-derived neo-epitope, demonstrating its contribution to
cartilage breakdown. Thus, this growth factor has a complex
pathophysiological role in joint diseases depending variably
on cartilage protection, bone remodelling and synovial
inﬂammation.
Peroxisome proliferators-activated receptors (PPAR) are
ligand-activated nuclear transcription factors belonging to
the nuclear hormone receptor superfamily13. PPAR bind,
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proliferator-response elements (PPRE) located in the
promoter of numerous genes involved in glucose and lipid
homeostasis, and regulate their expression upon activation
by agonists. PPAR consist of three mammalian subtypes,
PPARa, PPARb/d and PPARg, that are encoded by sepa-
rate genes and differ in their tissue distribution14 and ligand
speciﬁcity15. As a major component of their speciﬁcity for
one receptor isotype, PPAR ligands differ greatly in their
binding afﬁnity between endogenous compounds and
synthetic agonists. Thus, arachidonic acid metabolites, as
leukotriene B4 for PPARa, prostaglandin I2 for PPARb/d or
15-deoxy-prostaglandin J2 (15d-PGJ2) for PPARg
15 are
much less potent than pyrixinic acid (Wy14643) or ﬁbrates
for PPARa, GW501516 for PPARb/d or thiazolidinediones
for PPARg16. Albeit there is some overlapping, activation
of PPAR isotypes is associated with major functions includ-
ing oxidation of fatty acids in liver (mainly PPARa) and skel-
etal muscle (mainly PPARb/d) or differentiation of
adipocytes in adipose tissue (mainly PPARg), opening
insight to the treatment of metabolic syndrome and cardio-
vascular diseases17. PPAR are also implicated in the
control of the inﬂammatory response18 and of epithelial repair
pathways, with a key contribution of PPARb/d and PPARg
to skin wound healing and liver or kidney ﬁbrosis, respec-
tively19. PPAR are expressed in articular cells20 and their
activation is associated with a reduced production of inﬂam-
matory cytokines and less activation ofMMPs21 in cell culture
systems or experimental arthropathy22. Although most stud-
ies were done with the endogenous PPARg agonist 15d-
PGJ2 or with thiazolidinediones, recent studies demonstrate
that agonists of other PPAR isotypes may also have patho-
logical relevance to joint cells. Thus, interleukin-1 (IL-1)b-
induced expression of IL-1Ra was promoted by PPARa
agonists in rabbit chondrocytes23 while being potentiated
by activation of PPARb/d in rat synovial ﬁbroblasts24. PPAR
agonists may act therefore through activation of one or other
PPAR isotype in joint cells.
Beside their classical cytokines’ suppressive and metallo-
proteases’ regulatory properties, PPAR agonists can inhibit
the synthesis of extracellular matrix components in several
cell types. Collagen synthesis is inhibited by thiazolidine-
diones in mesangial cells from diabetic rats25 and by
Wy14643 in hepatic stellate cells from rats with cholestatic
liver ﬁbrosis26. Similarly, ﬁbronectin synthesis is inhibited by
pioglitazone in human kidney ﬁbroblasts27 whereas expres-
sion of decorin induced by non-esteriﬁed fatty acids is
reduced by darglitazone, another thiazolidinedione, in
human smooth muscle cells28. In these cell types, PPAR
agonists suppress also the stimulatory effect of TGF-b on
collagens29e31 and ﬁbronectin32 synthesis. Such inhibition
of extracellular matrix synthesis by PPAR agonists contrib-
utes to their preventive effect on ﬁbrosis in skin30, lung31,
kidney33 or liver26. Thus, activation of PPAR is associated
with a reduced synthesis of matrix components, which
has therapeutical relevance in clinical situations of extracel-
lular matrix overload but may be deleterious in diseases
characterized by extracellular matrix depletion, such as ad-
vanced OA.
When considering the anti-ﬁbrotic effect associated with
PPAR activation in many organs and the stimulatory effect
of TGF-b on extracellular matrix synthesis in cartilage, we
investigated the ability of synthetic agonists of the three
PPAR isotypes (a, b/d or g) to affect TGF-b1-induced
changes in PGs’ synthesis in rat chondrocytes embedded
in alginate beads. Using a panel of PPAR target genes
and control experiments with isotype-selective antagonists,we demonstrated that Wy14643, GW501516 and rosiglita-
zone (ROSI) induced preferentially PPARa, PPARb/d and
PPARg-dependent responses, respectively. In our culture
system, we showed that the stimulating effect of TGF-b1
on PG synthesis and deposition was reduced by all PPAR
agonists, with major changes for ROSI. Genes encoding
enzymes involved in glycosaminoglycans’ (GAGs) side
chains’ synthesis were poorly affected by TGF-b1 and
PPAR agonists, suggesting that PGs’ depletion by PPAR
agonists was supported mainly by inhibition of core protein
expression. We demonstrated further that PPAR agonists
affected differently several signalling pathways known to
control aggrecan gene expression, with early TGF-b1-in-
duced phosphorylation of Smad2/3 and ERK1/2 being
reduced by ROSI over GW501516 but not by Wy14643
and late TGF-b1-induced prostaglandin E2 (PGE2) produc-
tion being inhibited by Wy14643 over GW501516 but not by
ROSI. We demonstrated ﬁnally that the inhibitory effects of
PPAR agonists occurred in an isotype-selective manner
since inhibition of TGF-b1-induced expression of aggrecan
was reversed by a PPARa antagonist for Wy14643 and
a PPARg antagonist for ROSI, without consistent effect of
either antagonist on GW501516.
Materials and methods
CHONDROCYTE ISOLATION AND CULTURE IN ALGINATE
Normal articular cartilage was obtained from femoral
heads of Wistar male rats (150e175 g; Charles River, L’Ar-
bresle, France) killed under dissociative anaesthesia [ket-
amine (Me´rial, Lyon, France) and acepromazine (Sanoﬁ
Sante´ Animale, Libourne, France)] in accordance with na-
tional animal care guidelines, after approval by our internal
ethics committee. Chondrocytes were isolated by sequen-
tial enzymatic digestion of head caps using 0.15% pronase
and 0.2% collagenase B (Roche Molecular Biochemicals,
Meylan, France), then washed two times in phosphate buff-
ered saline (PBS) and cultured to conﬂuence in 75 cm2
ﬂasks at 37C in a humidiﬁed atmosphere containing 5%
CO2. The medium used was Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) supplemented with L-glutamine (2 mM),
penicillinestreptomycin (50 mg/ml), amphotericin B (0.5 mg/
ml) and 10% heat-inactivated foetal calf serum (FCS) (InVi-
trogen, Cergy Pontoise, France). After two passages, chon-
drocytes were encapsulated in alginate beads as follows:
cells were suspended in a 1.2% sterile solution of medium
viscosity alginate (SigmaeAldrich, Saint Quentin-Fallavier,
France) at a concentration of 5 106 cells/ml and dis-
pensed drop-wise into a 102 mM CaCl2 solution via a 22-
gauge needle attached to a syringe. After instantaneous
gelation, beads were allowed to further their polymerization
for 15 min in CaCl2 solution before three washes in sterile
0.15 M NaCl solution followed by two washes in complete
culture medium. The beads were maintained in complete
culture medium for 7 days at 37C in a humidiﬁed atmo-
sphere of 5% CO2 before experiments.
STUDY DESIGN
After 7 days of culture, beads were transferred into
culture medium containing 1% FCS and were maintained
under low FCS conditions throughout the experiments.
In a ﬁrst experiment, synthetic PPAR agonists were
added to chondrocytes’ beads to check for their selectivity
proﬁle using isotypes-speciﬁc PPAR target genes:
acyl-CoA oxidase (ACO) for PPARa, mitochondrial carnitin
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nectin for PPARg. The compounds used were ROSI
(1e10 mM; Cayman Chemical, Ann Arbor, MI) as represen-
tative of PPARg agonists, Wy14643 (Wy, 30e100 mM;
Calbiochem, Meudon, France) as representative of PPARa
agonists and GW501516 (GW, 0.1e100 nM; Alexis Bio-
chemicals, Paris, France) as representative of PPARb/d ag-
onists. The dependency on PPAR isotype was controlled in
the presence of speciﬁc antagonists GW6471 (10 mM;
Tocris Bioscience, Paris, France) for PPARa and
GW9662 (10 mM; Cayman Chemical) for PPARg. PPAR
ligands were dissolved in Dimethyl-Sulfoxide, which was
also added as vehicle to control cells at a ﬁnal concentration
of less than 0.2% (v/v).
In a second set of experiments, the effect of selected con-
centrations of PPAR agonists [ROSI (10 mM), Wy14643
(100 mM) or GW501516 (100 nM)] was studied on TGF-
b1-induced (10 ng/ml; Peprotech Tebu, Le Perrey en Yve-
lines, France) changes in PGs’ metabolism and signalling
events. In all experiments, agonists were added 2 h before
TGF-b1. PGs-related responses were studied 48 h (gene
expression) or 72 h (matrix metabolism) after addition of
TGF-b1. After preliminary kinetic studies, phosphorylation
of Smad2/3 or ERK1/2 and production of PGE2 were stud-
ied 1 h and 24 h after addition of TGF-b1, respectively.
In a third set of experiments, the contribution of each
PPAR isotype to agonists-induced changes in PGs’ metab-
olism, namely TGF-b1-induced expression of aggrecan and
TGF-b1, was controlled with the speciﬁc antagonists
GW6471 and GW9662 added at the same time as PPAR
agonists.
ASSAY FOR CHONDROCYTE VIABILITY
Cell viability was assessed by the mitochondrial-depen-
dent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT, SigmaeAldrich) into formazan.
Brieﬂy, cells were incubated for 48 h at 37C in the presence
or absence of TGF-b1 and/or PPAR agonists (added 2 h be-
fore TGF-b1when co-incubated) in lowFCS (1%) cultureme-
dium. Chondrocytes’ beads were incubated further with MTT
(1 mgml1 ﬁnal concentration) for 4 h at 37C. After removal
of culture medium, beads were solubilized in citrateeEthyle-
nediaminetetraacetate (EDTA) buffer (55 mM/50 mM; pH
6.8) and chondrocytes’ viability was assessed after addition
of lysing buffer (20% w/v of sodium dodecyl sulphate [SDS]
in a 50% aqueous solution of dimethyl formamide (DMF),
pH 4.7). After 24 h of incubation at 37C, solubilization of
formazan crystals was quantiﬁed by measurement of absor-
bance at 580 nm on aMultiskanmicroplate reader (Labsys-
tems, Montigny-le-Bretonneux, France).
REGIONAL LOCALIZATION OF GAGS IN BEADS
After stimulation with TGF-b1, in the presence or absence
of PPAR agonists, alginate beads were ﬁxed for 4 h at 20C
in a 4% paraformaldehyde solution (pH 7.4) (SigmaeAl-
drich) containing 100 mM sodium cacodylate and 10 mM
CaCl2, then washed overnight in 100 mM sodium cacody-
late buffer containing 50 mM BaCl2. Samples were dehy-
drated in graded solutions of ethanol, then embedded in
parafﬁn and cut into sections (5 mm thickness), before stain-
ing with Alcian blue (SigmaeAldrich) (1% w/v in acetic acid
3%) for the visualization of PGs’ deposition. Sections (n¼ 5
beads per condition) were observed on three different areas
at a magniﬁcation 100 with a photonic microscope (Nikontype 104, Tokyo, Japan) and staining intensity was
analysed using NIH Image software (NIH/ImageJ,
http://rsb.info.nih.gov).
ASSAY FOR GAGS IN FURTHER REMOVED MATRIX (FRM)
After stimulation with TGF-b1, in the presence or absence
of PPAR agonists, alginate beads (50 per condition) were
dissolved in citrateeEDTA buffer (55 mM/50 mM; pH 6.8)
for 10 min at 37C. The suspension was centrifuged for
15 s at 10,000 rpm to separate the cells surrounded by
‘‘cell-associated-matrix’’ (CM, the pellet) from components
originating predominantly from the ‘‘interterritorial matrix’’
further removed from the cells (FRM; alginate supernatants)
as described34. Alginate supernatants were further incu-
bated for 2 h at 60C in papain buffer [NaH2PO4 (0.2 M),
EDTA (0.001 M), dithiotreitol (0.001 M) and papain
(5 U/ml)] to prevent non-speciﬁc interactions of 1.9-di-
methyl-methylene blue (DMB, SigmaeAldrich) with pro-
teins, and enzymatic digestion was stopped by addition of
sodium mono-iodoacetate (Merck, Nogent-sur-Marne,
France) at a ﬁnal concentration of 10 mM. Then, GAGs
were extracted from supernatants with an equal volume of
8 M guanidineeHCl (GuHCl, SigmaeAldrich) in 0.05 M so-
dium acetate buffer pH 5.8 for 48 h at 60C, followed by
centrifugation at 10,000 rpm for 20 min at 4C. The super-
natants were discarded and the pellets were washed suc-
cessively ﬁve times with PBS 1 (for optimal reduction of
alginate’s interference with GAGs) then with ethanol 70%
(for eliminating the interference of GuHCl with GAGs).
The washed pellets containing GAGs were dried for
20 min at room temperature before solubilization in 500 ml
Tris/HCl buffer (50 mM, pH 8). The metachromatic reaction
of GAGs with DMB was performed by adding 40 ml of each
diluted sample (1/40eme) to 960 ml of DMB solution [32 mg
of DMB, 5 ml ethanol 70 and 4 ml formic acid solubilized
in 1 L formate buffer 0.4% (w/v)]35. The rapid measurement
of absorbance at 525 nm on a UV1601 spectrophotometer
(Shimadzu, ScienceTech, Paris, France) was used to calcu-
late the amounts of GAGs in the samples using shark chon-
droitin-6-sulphate (SigmaeAldrich) as a standard and cell
free alginate beads as a blank.
CHONDROCYTES’ PGS’ SYNTHESIS
After stimulation with TGF-b1, in the presence or absence
of PPAR agonists, alginate beads (ﬁve beads per well) were
incubated in complete low FCS DMEM medium containing
10 mCi/ml of sodium sulphate 35S[Na2SO4] for 4 h at 37
C
in a 5% CO2 humidiﬁed atmosphere. Alginate beads were
washed ﬁve times with 0.15 M NaCl and solubilized over-
night in citrateeEDTA buffer (55 mM/50 mM; pH 6.8). The
35SO4-labelled PGs’ content was assessed on aliquots of
digested samples by liquid scintillation counting (Packard,
Rungis, France) with an LKB 1214 counter (Wallac, Perkin
Elmer, Courtabœuf, Paris Cedex, France).
ASSAY FOR PGE2
PGE2 levels were assessed in the same culture superna-
tants 24 h after addition of TGF-b1, using a commercially
available enzyme immunoassay kit (Assay Designs Inc,
Ann Arbor, MI, USA), according to the manufacturer’s in-
structions. This assay showed no signiﬁcant cross-reactivity
with other prostaglandins and the limit of detection was
39.1 pg/ml.
496 P. E. Poleni et al.: Agonists of PPAR reduce TGF-b-induced PG productionWESTERN BLOTTING FOR SMAD2/3, ERK1/2 AND P38-MAPK
After stimulation with TGF-b1, in the presence or ab-
sence of PPAR agonists, alginate beads were dissolved
in citrateeEDTA buffer (55 mM/50 mM; pH 6.8) for
10 min at 37C, then centrifuged at 10,000 rpm for 15 s.
The supernatants were discarded and the pellets were
washed ﬁve times with PBS 1 before suspension in
200 ml of Laemmli buffer 1 (SigmaeAldrich). Total DNA
was sheared by sonication and pelleted by centrifugation
at 3000 rpm for 10 min. The supernatants were further
collected and 20 ml of each protein sample was analysed
by SDS-polyacrylamide gel electrophoresis (10% acrylam-
ide) and electroblotted onto polyvinylidene diﬂuoride
membrane. After one night at 4C in 5% (w/v) blocking
buffer, membranes (Immobilon; Waters, St. Quentin-en-
Yvelines, France) were blotted 2 h at room temperature
with primary antibodies against phospho or non-phospho
Smad2/3, p44/p42-MAPK (ERK1/2) or p38-MAPK (Cell
Signaling, Beverly, MA), and against b-actin (Sigma). All
antibodies were diluted 1:1000. After three washings with
Tris buffered saline (TBS)-Tween [(pH 7.6, 50 mM Tris
containing 150 mM NaCl and 0.1% Tween20 (v/v)], blots
were incubated for 1 h at room temperature with horserad-
ish peroxydase-conjugated secondary antibodies (Cell
Signaling) diluted at 1:2000 in 1% (w/v) blocking buffer.
After four washings with TBS-Tween, speciﬁc proteins
were detected by chemiluminescence with the Phototope
Detection system (Cell Signaling) according to the
manufacturer’s instructions. Densitometric scans were
analysed using NIH Image software (NIH/ImageJ,
http://rsb.info.nih.gov).
RNA EXTRACTION AND REAL TIME POLYMERASE
CHAIN REACTION (PCR)
After stimulation with TGF-b1, in the presence or absence
of PPAR agonists, alginate beads were dissolved in citra-
teeEDTA buffer (55 mM/50 mM; pH 6.8) for 10 min at
37C, then centrifuged at 10,000 rpm for 15 s. The superna-
tants were discarded and the pellets were washed ﬁve
times with PBS before extraction of total RNA using an
RNeasy minikit (Qiagen, Valencia, CA). Total RNA
(500 ng) were reverse transcribed in a volume of 20 ml con-
taining 4 ml of 5 First Strand Buffer, 20 mM hexanucleoti-
des random primers, 1 ml of Recombinant Ribonuclease
Inhibitor (RNA-se OUT 40 U/ml), 2 ml of dNTP (5 mM), 2 ml
of dithiotreitol (0.1 M) and 1 ml of Moloney murine leukaemia
virus (M-MLV; 200 U/ml) (Invitrogen) for 1 h 30 min at 37C
and 5 min at 95C. To quantify aggrecan, xylosyl transfer-
ase-1, chondroitin-4-sulphate-transferase, chondroitin-6-
sulphate-transferase, TGF-b1, adiponectin, ACO, CPT-1mRNAs expression, real time PCR was performed using
the Lightcycler Technology (Roche) and the SYBRgreen
master mix system (Qiagen, Courtabœuf, France). The
sequences of the primers used and corresponding prod-
ucts’ lengths are summarized in Table I. After ampliﬁcation,
a melting curve was plotted to determine the melting tem-
perature of each PCR product; their sizes were checked
on a 2% agarose gel stained with ethidium bromide
(0.5 mg/ml). Each run included positive and negative con-
trols. The transcript level of the housekeeping gene RP29
was determined in parallel for each sample and data are ex-
pressed as the normalized ratio of mRNA level of each
gene of interest over the RP29 gene.
STATISTICAL ANALYSIS
Data are expressed as mean standard error of the
mean (S.E.M.) of three to ten values obtained from one to
three separate experiments. Comparisons were made by
ANOVA, followed by Fisher’s protected least signiﬁcant dif-
ference test using StatView 5.0 software (SAS Institute,
Cary, NC). Statistically signiﬁcant differences from the con-
trol are indicated as *, P< 0.05; **, P< 0.01; ***, P< 0.001,
from TGF-b1-treated cells as #, P< 0.05; ##, P< 0.01; ###,
P< 0.001, and from ‘‘TGF-b1þPPAR agonists’’ or ‘‘PPAR
agonists’’-treated cells as x, P< 0.05; xx, P< 0.01; xxx,
P< 0.001.
Results
SELECTIVITY OF SYNTHETIC PPAR AGONISTS
FOR PPAR TARGET GENES
Preliminary experiment using the MTT assay showed no
loss of viability of rat chondrocytes exposed to PPAR ag-
onists and/or antagonists in the concentration range
tested (data no shown). In our experimental conditions,
ACO mRNA level was increased moderately (around
1.4-fold) by Wy14643 (100 mM), while being reduced
strongly by ROSI (1 or 10 mM) and GW501516 (only
100 nM) (Fig. 1). CPT-1 mRNA level was up-regulated
by ﬁve-fold by GW501516 (100 nM) while being induced
around two-fold by Wy14643 and ROSI (Table II). Adipo-
nectin mRNA level was increased by ROSI in dose-related
manner (3.9-fold at 10 mM), while being reduced margin-
ally by GW501516 (100 pM) or the highest concentration
of Wy14643 (100 mM) (Fig. 1). These data supported
that, in our experimental conditions, Wy14643 behaved
as a selective PPARa agonist at 100 mM, GW501516 as
a selective PPARb/d agonist at 100 nM and ROSI as a se-
lective PPARg agonist at 10 mM.Table I
Primers used for real time PCR and corresponding products’ lengths
Genes Primer sequence, forward Primer sequence, reverse Tm ((C) PS (pb)
RP29 50-AAG ATG GGT CAC CAG CAG CTC TAC TG-30 50-AGA CGC GGC AAG AGC GAG AA-30 59 67
Aggrecan 50-ACA CCC CTA CCC TTG CTT CT-30 50-AAA GTG TCC AAG GCA TCC AC-30 59 124
Xyl-transferase 1 50-GTC GCA CCT CTG ACC TTC TC-30 50-CCA GGC TTC TAG TGC TGT CC-30 61 201
C4S-transferase 50-CAT GCC ACA TCC ACT ACG AC-30 50-AAC TCC GTG GTC ATC TCG TC-30 60 151
C6S-transferase 50-CCT CGG AGC AGT TTG AGA AG-30 50-GTT GGT GAG TGA GGC GGT AT-30 60 131
TGF-b1 50-CTG CTG ACC CCC ACT GAT A-30 50-TGA AGC GAA AGC CCT GTA TT-30 57 103
ACO 50CCAATCACGCAATAGTTCTGG-30 50-CGC TGT ATC GTA TGG CGA T-30 58 362
Adiponectin 50-AAT CCT GCC CAG TCA TGA AAG -30 50-TCT CCA GGA GTG CCA TCT CT-30 58 433
CPT-1 50-ATG ACG GCT ATG GTG TCT TCC-30 50-GTG AGG CCA AAC AAG GTG AT-30 58 154
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Fig. 1. Selectivity of synthetic PPAR agonists for PPAR target genes in chondrocytes. Rat chondrocytes, embedded in alginate beads
(5 104 cells/bead) were exposed or not to Wy14643 (10e30 mM, PPARa agonist), GW501516 (0.1e100 nM, PPARb/d agonist) or ROSI
(1e10 mM, PPARg agonist) for 48 h. Data expressed as mean levels of mRNA of speciﬁc target genes normalized to RP29 (n¼ 4e8): (A)
ACO for PPARa; (B) CPT-1 for PPARb/d; (C) adiponectin for PPARg.REVERSION OF PPAR TARGET GENES’ EXPRESSION
BY PPAR ANTAGONISTS
The dependency on PPAR isotype was controlled with
speciﬁc antagonists. Experiment showed that GW6471 sup-
pressed selectively the inducing effect of Wy14643 on ACO
expression, although it was itself inhibitory (60%) on ACO
expression and stimulatory (1.6-fold) on adiponectin ex-
pression (Fig. 2). Moreover, GW9662 reduced ROSI-in-
duced expression of adiponectin below control level,
although it reduced partly (60%) the stimulating effect of
GW501516 on CPT-1 mRNA level (Fig. 2). In basal condi-
tions, GW9662 stimulated ACO expression by two-fold
while reducing adiponectin expression by 45% (Fig. 2).
These results were consistent with GW6471 acting as
a PPARa antagonist with a marginal potency to activatePPARg, and GW9662 as a PPARg antagonist with a mar-
ginal potency to activate PPARa. These data also con-
ﬁrmed the isotype selectivity of 100 mM of Wy14643,
100 nM of GW501516 and 10 mM of ROSI and led us to
select these concentrations for subsequent experiments.
EFFECTS OF SELECTIVE PPAR AGONISTS ON TGF-
b1-INDUCED CHANGES IN PG METABOLISM
Preliminary experiments in the MTT assay were consis-
tent with a non-signiﬁcant proliferating effect of TGF-b1
(10 ng/ml) on chondrocytes embedded in beads (data not
shown). In these conditions, TGF-b1 stimulated the overall
content in GAGs by 3.5-fold [Fig. 3(A)] and their deposition
in the interterritorial matrix area by 6.2-fold withoutTable II
Effects of selective PPAR agonists on TGF-b1-induced expression of genes involved in PG synthesis in chondrocytes. Rat chondrocytes,
embedded in alginate beads (5 104 cells/bead), were exposed or not to Wy14643 (100 mM), GW501516 (100 nM) or ROSI (10 mM) for
2 h before stimulation with TGF-b1 (10 ng/ml), alone or in combination with PPAR agonists, for 48 h. Normalized mRNA levels of aggrecan,
xylosyl transferase-1 and chondroitin-(4 or 6)-sulphate-transferases quantified by real time PCR (n¼ 4). Data are expressed as mean S.E.M.
Statistically significant differences from the control are indicated as *, P< 0.05; **, P< 0.01; ***, P< 0.001 and from TGF-b1-treated cells as #,
P< 0.05; ##, P< 0.01; ###, P< 0.001
PPAR agonists Genes/RP29 Aggrecan Xylosyl
transferase-1
Chondroitin-4-sulphate-
transferase
Chondroitin-6-sulphate-
transferase
None w/o TGF-b1 1.00 0.13 1.00 0.06 1.00 0.06 1.00 0.11
þ TGF-b1 12.4 2.56*** 1.44 0.08* 0.76 0.15 0.68 0.08
Wy14643 w/o TGF-b1 0.45 0.20* 1.72 0.18* 2.73 0.14** 0.51 0.02**
þ TGF-b1 3.44 1.10### 1.89 0.62 1.41 0.27# 0.66 0.24
GW501516 w/o TGF-b1 0.70 0.11 1.30 0.15 2.60 0.10** 1.30 0.15
þ TGF-b1 3.40 0.73### 1.23 0.17 1.64 0.21# 1.25 0.18#
Rosiglitazone w/o TGF-b1 0.48 0.07** 4.14 1.05** 3.00 0.53** 1.48 0.18**
þ TGF-b1 2.40 0.52### 3.07 0.82## 1.14 0.02# 1.14 0.06#
498 P. E. Poleni et al.: Agonists of PPAR reduce TGF-b-induced PG productionmodifying their pericellular localization [Fig. 3(B)]. Besides,
PGs’ synthesis was increased by approximately four-fold
[Fig. 3(C)] and the mRNA level of aggrecan was increased
by 12.5-fold without marked changes in the expression level
of xylosyl transferase-1, chondroitin-4 and -6 transferases
(Table II).
In the presence of PPAR agonists, the MTT assay was
not signiﬁcantly reduced except for the highest dose of
ROSI (data not shown). The stimulating effect of TGF-b1
on GAGs’ content was suppressed from 90% for
GW501516 to below basal level for ROSI [Fig. 3(A)] and
their deposition in interterritorial matrix was reduced
dramatically (from 73% for Wy14643 to 95% for ROSI)
[Fig. 3(B)]. The enhancing effect of TGF-b1 on PG synthe-
sis was also reduced by PPAR agonists (from 24% for
Wy14643 to 44% for ROSI), but the basal rate of radiola-
belled sulphate incorporation was slightly increased by
Wy14643 while being slightly reduced by ROSI
[Fig. 3(C)]. TGF-b1-induced expression of aggrecan was
inhibited from 76% for Wy14643 to 83% for ROSI, but
all PPAR agonists tended to decrease the basal level of
aggrecan (Table II). In contrast, PPAR agonists increased
moderately the basal levels of mRNA for xylosyl transfer-
ase-1, chondroitin-4 and -6 sulphate transferases except
for Wy14643 on chondroitin-6 sulphate transferase, and
a reproducible decrease was observed only for chondroi-
tin-4 transferase in the presence of TGF-b1 (Table II). For
most TGF-b1-induced responses, the maximal inhibitory
effect was observed with ROSI [Fig. 3(AeC)], a ﬁnding con-
sistent with its ability to decrease mitochondrial activity in
the MTT assay.
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Fig. 2. Reversion of PPAR target genes’ expression by selective
antagonists in chondrocytes. Rat chondrocytes, embedded in
alginate beads (5  104 cells/bead), were exposed or not to
Wy14643 (100 mM), GW501516 (100 nM), or ROSI (10 mM), in
the presence or absence of PPARa (GW6471, 10 mM) or PPARg
(GW9662, 10 mM) antagonists for 48 h. Data are expressed as
mean S.E.M. of normalized mRNA levels for ACO, CPT-1 or adipo-
nectin quantiﬁed by real time PCR (n¼ 4). Statistically signiﬁcant
differences from the control are indicated as *, P < 0.05; **,
P< 0.01, ***, P< 0.001, and from ‘‘PPAR agonists’’-treated cells
as x, P< 0.05; xx, P< 0.01; xxx, P< 0.001.EFFECTS OF SELECTIVE PPAR AGONISTS ON TGF-
b1-INDUCED SIGNALLING PATHWAYS
Time course effect of Smad2/3, ERK1/2
and p38-MAPK phosphorylation by TGF-b1
In our experimental system, TGF-b1 induced a fast phos-
phorylation of Smad2/3 which was maximal around 1 h,
whereas no signiﬁcant variation was observed on p38-
MAPK [Fig. 4(A)]. TGF-b1 promoted also the phosphoryla-
tion of p44- and p42-MAPK although the kinetics revealed
an early (1e2 h) and a late (24 h) activation of this pathway
[Fig. 4(A)]. This led us to study the effects of PPAR agonists
on signalling events 1 h after the addition of TGF-b1 and to
consider only Smads and ERK pathways.
Effects of agonists on TGF-b1-induced
phosphorylation of Smad2/3 and ERK1/2
In chondrocytes’ beads, TGF-b1-induced phosphoryla-
tion of Smad2/3 (4.5-fold) was reduced by 50% to
75% by GW501516 and ROSI, respectively, whereas
Wy14643 was ineffective [Fig. 4(B)]. At the same time,
TGF-b1-induced phosphorylation of p44-MAPK (2.5-fold)
was completely suppressed by GW501516 and ROSI while
being reduced slightly by Wy14643 [Fig. 4(C)]. Similar
results were observed on TGF-b1-induced phosphorylation
of p42-MAPK (3.5-fold) with a 70% to 75% decrease
obtained in the presence of GW501516 and ROSI, respec-
tively [Fig. 4(C)].
EFFECTS OF SELECTIVE PPAR AGONISTS ON TGF-
b1-INDUCED PGE2 PRODUCTION
In our experimental conditions, TGF-b1 stimulated PGE2
production by 3.9-fold at 24 h. This stimulating effect was
abrogated by Wy14643 and inhibited by 68% by
GW501516, whereas ROSI was marginally inhibitory
(Fig. 5). Control experiment showed that the basal produc-
tion of PGE2 was decreased (59%) by Wy14643 but
stimulated (1.9-fold) by ROSI.
REVERSION OF THE ANTI-ANABOLIC POTENCY OF PPAR
AGONISTS BY SELECTIVE ANTAGONISTS
Effects on aggrecan mRNA expression
TGF-b1-induced increase in aggrecan mRNA level (nine-
fold increase) was neither affected by the PPARa
antagonist GW6471 (10-fold increase) nor by the PPARg
antagonist GW9662 (11-fold increase) [Fig. 6(A)]. As
observed previously, TGF-b1-induced aggrecan expression
was reduced by all PPAR agonists (from 77% for
Wy14643 to below basal level for ROSI). In the presence
of GW6471, the inhibitory potency of Wy14643 was relieved
whereas those of GW501516 and ROSI remained un-
changed [Fig. 6(A)]. Corollary, the inhibitory potency of
ROSI was relieved in the presence of GW9662, whereas
those of Wy14643 and GW501516 remained unaffected
or poorly affected, respectively [Fig. 6(A)]. Control experi-
ment showed that GW6471 and GW9662 did not modify
the basal level of aggrecan mRNAs whereas most PPAR
agonists were inhibitory (data not shown).
Effects on TGF-b1 mRNA expression
The stimulating effect of TGF-b1 on the mRNA level of
TGF-b1 (6.3-fold increase) was neither affected by the
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PPARg antagonist GW9662 (5.3-fold increase) [Fig. 6(B)].
As observed previously, TGF-b1-induced TGF-b1 expres-
sion was reduced by all PPAR agonists (from 59% for
Wy14643 to below basal level for ROSI). In the presence
of GW6471, the inhibitory potency of Wy14643 was relieved
whereas those of GW501516 and ROSI remained un-
changed [Fig. 6(B)]. Corollary, the inhibitory potency of
ROSI was relieved in the presence of GW9662, whereas
those of Wy14643 and GW501516 remained unaffected
or poorly affected, respectively [Fig. 6(B)]. Control experi-
ment showed that GW6471 and GW9662 did not modify
the basal level of TGF-b1 mRNAs whereas ROSI was
solely inhibitory (data not shown).
Discussion
In the present work, we investigated the potency of
selective PPAR agonists to impair anabolic effect of TGF-
b1 on PGs in chondrocytes. Therefore, experimental condi-
tions were selected to reproduce the tridimensionalenvironment of articular cartilage and to obtain an optimal
response to TGF-b1. Alginate was chosen as culture
system to maintain chondrocytes’ phenotype36 and produce
aggrecan with a compartmentalization thought to reproduce
the pericellular and territorial matrix areas and interterritorial
compartment of articular cartilage, respectively34. Chondro-
cytes’ beads were used at a time suitable to overcome early
cell death37 and to assume a reproducible synthesis of ex-
tracellular matrix components in response to growth fac-
tors34 without extensive cell proliferation38. The latter point
is of primary importance since PPAR agonists have well-
known antiproliferative effects in other cell types39. We
showed that, except for ROSI after 72 h of incubation,
none of the agonists impaired the MTT assay supporting
that our data were rather representative of changes in cell
metabolism than in cell proliferation. Preliminary dose-rang-
ing studies conﬁrmed that optimal biosynthetic responses of
rat cells were observed for 10 ng/ml of TGF-b1 in low (1%)
FCS culture medium, as reported for bovine chondrocytes38
or mouse cartilage40. In these experimental conditions,
TGF-b1 stimulated [35S]PGs and overall GAG content to
a similar extent while favouring their deposition in the
501Osteoarthritis and Cartilage Vol. 15, No. 5interterritorial matrix of beads. Maximal changes were ob-
served on aggrecan gene expression, which is a well-
known target gene of TGF-b141, whereas marginal changes
were noted for genes involved in the formation of the GAGs’
side chains. Thus, it is likely that PGs found in the beads’
matrix were essentially neosynthesized. Thus, the anabolic
effect of TGF-b1 on PGs’ metabolism was driven mainly by
the transcriptional activation of the aggrecan gene in rat
beads although increased C4S/C6S ratios were reported
in human42 TGF-b1-stimulated chondrocytes.
As many PPAR independent effects were reported for 15-
deoxy-D12,14prostaglandin J2 (15d-PGJ2)
43, a natural ago-
nist with a low binding afﬁnity to PPAR gamma, we used
only synthetic PPAR agonist with a high binding afﬁnity
for one PPAR isotype16 and conﬁrmed their selectivity using
a panel of PPAR target genes: ACO as representative for
PPARa44, mitochondrial CPT-1 as representative for
PPARb/d45 and adiponectin as representative for PPARg46.
In our culture system, the contribution of each PPAR iso-
type was further controlled by reversion experiments with
the selective PPARa antagonists GW647147 and the selec-
tive PPARg antagonist GW966248. Such pharmacological
approach was developed as a convenient surrogate to clas-
sical gene reporter or dominant negative strategies49,50
which were poorly adapted to our culture system. Indeed,
efﬁciency of non-viral transfection was low in primary rat
chondrocytes compared to other species69 and transgene
expression was shown to decrease gradually with time in
the alginate system51.
As expected, ACO expression was increased moderately
by Wy14643 whereas adiponectin expression was stimu-
lated more robustly by ROSI in rat chondrocytes. Expres-
sion of CPT-1 was induced by all PPAR agonists but with
a maximal response for GW501516. This result agreed
well with less restrictive dependency of CPT-1 towards
PPAR isotypes52 and the inﬂuence of tissue environment
on the response of a given target gene to PPAR agonists53.
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Fig. 5. Effects of selective PPAR agonists on TGF-b1-induced
PGE2 production in chondrocytes. Rat chondrocytes, embedded
in alginate beads (5  104 cells/bead), were exposed or not to
Wy14643 (100 mM), GW501516 (100 nM) or ROSI (10 mM) for 2 h
before stimulation with TGF-b1 (10 ng/ml), alone or in combination
with PPAR agonists, for 24 h. PGE2 level was measured by EIA
assays in culture supernatants (n ¼ 4). Data are expressed as
mean S.E.M. Statistically signiﬁcant differences from the control
are indicated as *P< 0.05; **, P< 0.01; ***, P< 0.001 and from
TGF-b1-treated cells as #, P< 0.05; ##, P< 0.01; ###, P< 0.001.The concentrations which were selected from this inducing
proﬁle on PPAR target genes were in the range of those
used previously to study the effect of Wy1464349,
GW50151624, or ROSI54 in articular cells. However, they
were far above those required for the transactivation of
chimeric murine or human PPAR receptors in cell-based
transfection assays55 and PPAR-dependent activities
were also reported at lower concentrations in rabbit chon-
drocytes23,50. These higher concentrations are supported
likely by species differences in the response of PPAR to
a given agonist56 and by the need to activate the whole
cellular machinery after crossing of the alginate and extra-
cellular matrix network34.
Reversion experiments demonstrated that GW647147 an-
tagonized selectively the expression of ACO induced by
Wy14643 and GW966248 the expression of adiponectin
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lective antagonists in chondrocytes. Rat chondrocytes, embedded
in alginate beads (5 104 cells/bead), were exposed or not for
2 h with Wy14643 (100 mM), GW501516 (100 nM), or ROSI
(10 mM), in the presence or absence of PPARa (GW6471, 10 mM)
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502 P. E. Poleni et al.: Agonists of PPAR reduce TGF-b-induced PG productioninduced by ROSI. In TGF-b1-stimulated cells, GW6471 re-
versed also the inhibitory effect of Wy14643 on aggrecan
and TGF-b1 expression whereas GW9662 reversed the
inhibitory effect of ROSI on these parameters. These data
were consistent with Wy14643 and ROSI controlling
PPARa- and PPARg-dependent responses, respectively,
both in the PPAR and aggrecan systems. The effect of
GW501516 was suppressed partly by GW9662, as well
on induction of CPT-1 as on the inhibition of TGF-b1-in-
duced aggrecan expression. This could reﬂect a weak
antagonism of PPARb/d in chondrocytes since GW9662
was shown to interfere possibly with isotypes other than g
in PPAR reporter cell lines57. Nonetheless, this effect
remained negligible compared to its covalent inhibition of
PPARg48 which reproduced the effect of a dominant nega-
tive strategy in synovial ﬁbroblast49 while antagonizing the
transcriptional activity of ROSI in SW-1353 chondrosar-
coma cells58. Although one cannot exclude that agonists
may act on other intracellular pathways than PPAR, our
data strongly supported that Wy14643, GW501516 and
ROSI were responsible for PPARa, b/d and g-dependent
responses in rat chondrocytes, respectively.
In the present work, we showed for the ﬁrst time that the
stimulating effect of TGF-b1 on GAG content and deposition
was reduced dramatically by PPAR agonists whereas the
production of newly synthesized PGs was reduced by at
least 25%. At the molecular level, TGF-b1-induced expres-
sion of aggrecan was inhibited by more than 75% by all
PPAR agonists without marked changes on genes involved
in GAGs’ side chains’ synthesis. This effect was seen
independently of the selectivity for a given PPAR isotype,
although with the following rank order of potency:
ROSI>GW501516Wy14643. The higher potency of
ROSI was not supported by a higher level of PPARg since
we conﬁrmed that all PPAR isotypes were expressed at
the mRNA level in rat chondrocytes, with PPARb/d being
the most abundant (data not shown). However, in contrast
to our previous reports of a selective decrease of the g iso-
type in response to pro-inﬂammatory cytokines20,24, we ob-
served that the expression of all PPAR isotypes was
reduced signiﬁcantly in response to TGF-b1 (data not
shown). Thus, the ability of selective PPAR agonists to
bind to a given isotype was comparable in resting and
TGF-b1-stimulated chondrocytes. The inhibitory effect of
ROSI on chondrocyte PGs was in line with the ability of
PPARg agonists to suppress decorin expression in human
arteries28 as well as TGF-b1-induced expression of other ex-
tracellular matrix components in mesangial cells36, skin ﬁ-
broblast30 or in pulmonary myoﬁbroblasts31. In contrast, no
anti-ﬁbrotic potency has been reported for PPARb/d agonists
whereas PPARa agonists were unable to suppress TGF-b1-
induced collagen synthesis in pulmonary myoﬁbroblasts31.
To clarify the contribution of either PPAR isotype to an
anti-TGF-b1 effect, we investigated the ability of agonists
to impair TGF-b1-induced signalling events thought to reg-
ulate aggrecan expression in chondrocytes59. Interestingly,
we demonstrated that early TGF-b1-induced phosphoryla-
tion of Smad2/3 was reduced by ROSI and GW501516
but not by Wy14643. As overexpression of Smad7, a well-
known inhibitory Smad, suppressed the stimulating effect
of TGF-b1 on PG synthesis in a murine chondrocyte cell
line60, it is likely that inhibition of the Smad pathway contrib-
uted to the inhibitory potency of ROSI and GW501516.
However, further studies are required to investigate if these
agonists were able to interact physically with Smad proteins
as PPAReligands complexes61 or to regulate aggrecan ex-
pression at the level of Smad-dependent promoter activityinduced by TGF-b30. We also demonstrated that the early
phosphorylation of ERK1/2 was reduced by ROSI and
GW501516 but not by Wy4643. Although its contribution
was reported primarily in TGF-b-induced cell growth62,63,
activation of ERK1/2 was shown to regulate TGF-b-induced
aggrecan gene expression59 and to interplay with other sig-
nalling pathways in chondrocytes59,63. Interestingly, inhibi-
tion of ERK1/2 and Smad2/3 phosphorylation by ROSI
and GW501516 was complementary and may reduce
TGF-b-induced expression of aggrecan gene with a different
time course59. In contrast, we showed that TGF-b1 failed to
activate p38-MAPK in our culture system, a ﬁnding consis-
tent with previous kinase assays on chondrocytes’ mono-
layers62 which did not support its major contribution to
PGs’ synthesis. This result is at variance with the blunting
effect of p38-MAPK inhibitors on TGF-b1-induced PGs’ syn-
thesis in human chondrocytes64, but species dependent dif-
ferences were reported for the contribution of p38-MAPK
pathway in cartilage65.
We demonstrated ﬁnally that the stimulating effect of TGF-
b1 on PGE2 synthesis was reduced by Wy14643 and
GW501516 but not by ROSI in chondrocytes’ beads. TGF-
b was reported to stimulate PGE2 production in growth plate
chondrocytes by activation of several enzymes of the arach-
idonic acid cascade66e68. Effect of PGE2 on chondrocytes’
functions depends strongly on differentiation and corre-
sponding expression of EP receptors69, with EP-1 and EP-
2 being shown to promote cell growth and PGs’ synthesis
in growth plate-derived chondrocytes67 and EP-2 to account
for the growth of mature articular chondrocytes70. TGF-b-de-
pendent PG production was shown to involve a protein
kinase C (PKC) signalling pathway66,67, which was sensitive
to EP-2-dependent activation of Protein kinase A (PKA) by
PGE2 in growth plate chondrocytes
67 whereas crosstalk be-
tween ERK, PKA and PKC was reported in mature cells63.
Although further studies are required to elucidate the direct
modulation of each signalling pathway by PPAR agonists,
our data suggested that inhibition of TGF-b1-induced
PGE2 synthesis by Wy14643 and GW501516 contributed
to their inhibitory effect on PG synthesis. Taken together,
our data were in favour of PPAR agonists being able to re-
duce TGF-b1-induced responses by distinct mechanisms
ranging from inhibition of PGE2 for Wy14643 to inhibition
of ERK1/2 and Smad2/3 phosphorylation for ROSI, with
GW501516 being effective on both. Such differences agreed
well with the recent demonstration that cloﬁbrate, a PPARa
agonist, and ROSI, a PPARg agonist, were able to reduce
IL-1-induced MMP-1 expression in rabbit chondrocytes by
promoting sIL-1Ra production23 or interacting on a compos-
ite PPRE/AP1 site in the MMP-1 promoter50, respectively.
From a physiopathological point of view, the inhibitory
potency of PPAR agonists on TGF-b1-induced PG synthe-
sis could theoretically be viewed as a reduction of the repair
capacity of articular cartilage. However, TGF-b has also
a key role in extracellular matrix remodelling by regulating
the balance between MMPs and their natural inhibitors4.
Thus, TGF-b was shown to stimulate MMP-13 depending
on the physiologic state of OA chondrocytes71 and to favour
MMP-972 or aggrecanase production12 while limiting the
catabolic potency of pro-inﬂammatory cytokines73. PPARa
or g agonists were demonstrated to down-regulate the
cytokine-induced expression of several MMPs21,23,50 or ag-
grecanase74 whereas n-3 polyunsaturated fatty acids,
which are putative PPAR agonists56, prevented the IL-1-in-
duced release of PG metabolites from cartilage explants75.
Our data suggest that PPAR agonists could also
interfere with TGF-b1-induced degradation of PG. As a
503Osteoarthritis and Cartilage Vol. 15, No. 5consequence, due to their dual cytokines- and TGF-b-sup-
pressive properties, PPAR agonists could protect cartilage
PGs variably depending on the imbalance between these
factors and/or the level of inﬂammation76. This could explain
part of the reduction of cartilage lesions that was reported
for ROSI5 or fenoﬁbrate77 in experimental polyarthritis and
for pioglitazone in the menisectomy model of OA22, since
a decreased expression of pro-inﬂammatory cytokines
was reported. Although, this must be conﬁrmed in vivo,
our data strongly suggest that PPAR agonists could be del-
eterious in situation of cartilage repair while being protective
in situation of cartilage degradation.
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